Skip to content

Effects of gonadotropin dosage on clinical outcomes of in vitro fertilization-embryo transfer

Effects of gonadotropin dosage on clinical outcomes of in vitro fertilization-embryo transfer

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021944
Enrollment
Unknown
Registered
2019-03-17
Start date
2019-03-21
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Group 1:Fixed dose
Group 2:Individualized dose

Sponsors

Northwest Women's and Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 43 Years

Inclusion criteria

Inclusion criteria: 1. Infertile couples scheduled for their first IVF/ICSI cycle; 2. Women age <43 years old; 3. Women who will receive either long protocol or gonadotropin-releasing hormone antagonist protocol; 4. AFC<10; 5. Iinformed consent obtained.

Exclusion criteria

Exclusion criteria: 1. Women with contraindication for pregnancy, such as severe endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney); 2. Couples undergoing PGD and PGS; 3. Women with sever uterine anomaly or severe hydrosalpinx; 4. Women with moderate or severe endometriosis; 5. Women with history of recurrent miscarriage.

Design outcomes

Primary

MeasureTime frame
Live birth attributable to the first ART cycle within 18 months of randomization;

Countries

China

Contacts

Public ContactXitong Liu
liuxitong1989@qq.com+86 13484620246

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026